



Translate Bio to Present at the Bank of America Securities Virtual 2020 Healthcare Conference

May 12, 2020

LEXINGTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the Bank of America Securities Virtual 2020 Health Care Conference on Thursday, May 14, 2020, at 9:00 a.m. ET.

A live webcast of the session will be accessible through the "Events and Presentations" page of the Company's website at investors.translate.bio. A replay of the webcast will be archived on the Translate Bio's website for 30 days following the presentation.

About Translate Bio

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease. Translate Bio's lead program is being developed as a treatment for cystic fibrosis (CF) and is in a Phase 1/2 clinical trial. The Company also believes its technology is applicable to a broad range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as infectious disease and oncology. For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.

Contacts for Translate Bio

Investors

Teri Dahlman

tdahlman@translate.bio

857-242-7792

Media

Maura Gavaghan

mgavaghan@translate.bio

857-242-7789



Source: Translate Bio, Inc.